Generate:Biomedicines’ Post

**Only put off until tomorrow what you are willing to die having left undone** **Aptose Biosciences Closes $8 Million Public Offering for Oncology Development** **Quiver AI Summary:** Aptose Biosciences Inc. has successfully completed a public offering, raising $8 million through the sale of 40 million common shares at $0.20 each. Additionally, the offering included warrants to purchase an additional 20 million shares, providing further funding for the company's oncology development. This financing round will enable Aptose Biosciences to advance its promising projects and drive innovation in the field of oncology. With this latest development, Aptose Biosciences demonstrates its commitment to revolutionizing cancer treatment and making significant advancements in the healthcare industry. As an experienced investment advisor, I recommend exploring investment opportunities in Aptose Biosciences. By investing in promising companies like Aptose Biosciences, investors can actively contribute to the advancement of healthcare solutions and potentially achieve significant returns. Don't miss out on the chance to be part of the future of healthcare. Act now and invest in Aptose Biosciences to make a positive impact on the world. #hsa #investing #healthcare #health #family #wellness 💪💼📈💊🏥🌍

🔥🚀 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐌&𝐀 𝐄𝐱𝐩𝐥𝐨𝐬𝐢𝐨𝐧 𝐢𝐧 2024! 🚀🔥 🤔 Did you know the number of biopharma M&A deals has more than doubled in Q1 of 2024 compared to last year? From 6 to 13, totaling 47 in the last twelve months! 📈 🎉 𝐁𝐢𝐠 𝐌𝐨𝐯𝐞𝐬 𝐢𝐧 𝐁𝐢𝐠 𝐏𝐡𝐚𝐫𝐦𝐚: • AstraZeneca shakes up oncology with deals for Fusion Pharmaceuticals & Gracell Biotechnologies! 🧬 • Merck Life Science acquires T-cell magic from Harpoon Therapeutics! 🎯 🌟 𝐓𝐡𝐢𝐬 𝐖𝐞𝐞𝐤’𝐬 𝐇𝐞𝐚𝐝𝐥𝐢𝐧𝐞𝐫𝐬: • Takeda could spend up to $1.2 billion on a new cancer fighter with Kumquat Biosciences Inc.! 🛡️ • Boehringer Ingelheim and Ochre Bio tackle liver disease with a billion-dollar RNA therapy bet! 🧪 • Ipsen is investing $1.8 billion in neuroscience R&D with Skyhawk Therapeutics! 🧠 🌐 With Big Pharma's unwavering interest, 2024 is set to be a groundbreaking year for biotech M&A. What’s your take? Could this be the boost we've been waiting for in innovation and competition? 💡 #Biotech #MergersAndAcquisitions #Innovation #PharmaIndustry #FutureOfPharma

✨ Unlocking Precision Oncology: Highlights from Tumour Models London Summit 2024 ✨ We’re thrilled to share that Dr. Vered Bar, VP of R&D at CURESPONSE, delivered an inspiring session on “Future-Proofing Pipeline Compounds with Breakthrough Functional Technology” during our hosted lunch at the Tumour Models London Summit 2024. Key Highlights from the Session: •The Science: Showcasing CURESPONSE’s innovative ex-vivo platform that preserves the tumor and its microenvironment intact, offering unparalleled human functionality insights. •Our Differentiation: How our unmatched accuracy empowers pharma and biotech companies to gain a competitive edge in drug development. •Pipeline Applications: Transforming discovery and clinical development for biologics, immuno-oncology therapies, ADCs, CAR-T cells, and beyond. •Proven Impact: Case studies from leading pharma companies demonstrating how our platform de-risks pipelines and optimizes drug development. •Ease of Collaboration: A seamless process to integrate our platform into R&D workflows. 👏 A special thank-you to Marinela Tice and Leah Elliott from Hanson Wade Group for organizing such an inspiring and collaborative summit. 📩 Missed the session? Let’s connect to explore how CURESPONSE can elevate your drug development strategy. #Innovation #PrecisionOncology #TumourModels #DrugDevelopment #Biotech #CURESPONSE

After inking an up to $6 billion partnership with Poseida Therapeutics in 2022, Roche is now paying $1 billion upfront to acquire all of its off-the-shelf cell therapy and genomic medicines partner. The Swiss pharma giant is gaining a pipeline of oncology, autoimmune and neurology treatment candidates. “We do really think this is only the beginning. And when you think about it this way, then the answer becomes almost a foregone conclusion that there is so much complementarity, there is so much potential, we should become one,” Aviv Regev, head of research and early development at Genentech, said in an interview with Endpoints News. #roche #poseida #sandiegobiotech #biotech #pharma #biotechacquisition #allogeneic #offtheshelf #celltherapy #genomicmedicines #multiplemyeloma #hemophiliaa #hereditaryangioedema

Coya Therapeutics announces that, as previously disclosed, Arun Swaminathan, Ph.D., has been promoted to Chief Executive Officer, effective today, November 1. He brings a wealth of strategic, business development, operational, and deal-making experience to help guide Coya in its next phase of corporate growth. Arun said: "We believe our combination therapeutic approach targeting neuroinflammation can unlock a new paradigm in neurodegenerative treatment. We are encouraged by data from the Phase 2 investigator-initiated trial in patients with mild to moderate Alzheimer’s disease treated with low-dose interleukin-2 (LD IL-2), shared at CTAD, validating our Treg platform." Read more in our latest press release: https://lnkd.in/egtQah8t $COYA #CoyaTherapeutics #CEO

It is with great pride that I share that BeiGene has been named the #2 biotechnology company of 2024 by the Healthcare Technology Report. This report highlights that our medicines have already treated more than one million individuals.    At BeiGene we believe that everyone should have access to innovative, life-changing medicines, regardless of their location. From the discovery of new therapies to scaling our commercial reach, we are committed to transform the biotechnology industry, creating impactful medicines that will be affordable and accessible to far more cancer patients around the world.    As we continue this mission, we are pursuing a broad and deep pipeline with the potential to address 80% of the world’s cancers by cancer type.   #PatientsFirst #BeiGeneCAN #HealthcareTechnologyReport   https://lnkd.in/eipFWY72

Paul Bravetti (PharmD, HEC Paris) is a strategic executive with a particular interest in scientific innovation and entrepreneurial adventures. He joined Brenus Pharma in 2020 and became Chief Executive Officer in 2022 with a clear mission, vision, and leadership to address current treatment limitations and make a significant impact for cancer patients. Thanks to his international experience in major pharmaceutical companies, he has successfully led the launches of therapeutics in immuno-oncology and biomolecular diagnostics across Europe and Asia. This experience has shaped his understanding of the biopharmaceutical industry and its unmet needs. Meet Paul Bravetti @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

Here is an interesting Blog on Marker-Driven Drug Development. Worth reading.

Attention, biotech and pharmaceutical pioneers! Our latest blog post unravels the thrilling 𝙍𝙚𝙫𝙤𝙡𝙪𝙩𝙞𝙤𝙣 𝙞𝙣 𝙈𝙚𝙙𝙞𝙘𝙞𝙣𝙚: 𝙈𝙖𝙧𝙠𝙚𝙧-𝘿𝙧𝙞𝙫𝙚𝙣 𝙏𝙖𝙧𝙜𝙚𝙩𝙚𝙙 𝘿𝙧𝙪𝙜 𝘿𝙚𝙫𝙚𝙡𝙤𝙥𝙢𝙚𝙣𝙩. Discover how this cutting-edge approach is transforming healthcare! Dive into the realm of precision medicine, where treatments are tailored to your unique molecular profile. Uncover the secrets of biomarker-guided therapies that unlock personalized treatment plans. Read the full blog post here: https://lnkd.in/dmsx8Hyb 𝗖𝗼𝗻𝗻𝗲𝗰𝘁 𝘄𝗶𝘁𝗵 𝘂𝘀 𝘁𝗼𝗱𝗮𝘆! Let's explore the future of medicine, together! Contact us to discuss you oncology trial program: 𝗶𝗻𝗳𝗼@𝗸𝗮𝗽𝗮𝗱𝗶.𝗰𝗼𝗺 #MarkerDrivenRevolution #PrecisionMedicine #BiotechInnovation #Pharma #Biotech #Oncology #CancerResearch #MakeADifference #ClinicalTrials

TLDR Biotech for June 20 - 23 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥𝐬 & 𝐋𝐚𝐛𝐞𝐥𝐬: Bristol Myers Squibb lands FDA ok for colorectal cancer treatment 🎉 + 7 more stories 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: Melodia Therapeutics acquires pre-clinical cathepsin C inhibitor from Alivexis 💼 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬: Eli Lilly presents positive Ph3 data for GIP/GLP-1 in sleep apnea 💤 + 1 more story 𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐞𝐬: Rapafusyn Pharmaceuticals raises $28M Series A 💰 + 1 more story 𝐈𝐏𝐎𝐬: Tectonic Therapeutics debuts on NASDAQ via reverse merger with AVROBIO 📈 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬: Biocon seeks partner for testing Ozempic generics in China 🤝 + 1 more story 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐀𝐜𝐜𝐞𝐬𝐬: Vertex and NHS reach reimbursement deal for cystic fibrosis treatments 🏥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡: Study shows AI can accelerate clinical trial enrolments 🤖 𝐋𝐚𝐲𝐨𝐟𝐟𝐬: Ginkgo Bioworks cuts 158 staff, with more expected 😟 + 1 more story All this and more in today's TLDR Biotech newsletter - link to the latest issue: https://lnkd.in/gxxHMN5q Or subscribe to get it straight to your inbox: https://lnkd.in/gh68uhTQ #tldrbiotech #biotechnews #pharmanews